Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
PR Newswire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Kazia executives to join Guggenheim healthcare conference fireside chat November 9
- ➤Webcast scheduled for 8:30 a.m. EST on November 9
- ➤Kazia management available for one-on-one investor meetings
- ➤Paxalisib is Kazia's lead investigational oral brain-penetrant PI3K/mTOR inhibitor
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference PR Newswire
SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that John Friend, MD, Chief Executive Officer, and Jeffrey Kraws, Head of Corporate Strategy & Development, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, being held November 9 to 11, 2026, in Boston, Massachusetts.
Get started
Create a free account to read the full story.